All In Biotech

NDA 019726 · Tersera

Zoladex

Goserelin Acetate · Implantation

Novel

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Dec 29, 1989

Approved uses

5

Original approval plus efficacy supplements

Registered trials

381

126 Phase 3, 47 recruiting

FAERS reports

13,568

12,237 serious, 2,422 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 24, 2026.

ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )]. 1.4 Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )]. 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal...

Mechanism: ZOLADEX is a synthetic decapeptide analogue of GnRH. ZOLADEX acts as an inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. In animal and in vitro studies, administration of goserelin resulted in the regression or inhibition of growth of the hormonally sensitive dimethylbenzanthracene (DMBA)-induced rat mammary tumor and Dunning R3327 prostate tumor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZOLADEX · GOSERELIN ACETATE EQ 3.6MG BASE · IMPLANT, IMPLANTATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Goserelin" as an intervention, any sponsor and status, largest first.

All 381 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,594
  • malignant neoplasm progression1,367
  • fatigue925
  • metastases to bone706
  • neutropenia680
  • nausea624
  • asthenia540
  • hot flush527
  • diarrhoea521
  • off label use493
  • pain492
  • arthralgia457

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004224
2005218
2006246
2007274
2008296
2009298
2010265
2011385
2012485
2013405
2014446
2015589
2016571
2017485
2018691
2019777
2020902
20211,190
20221,030
20231,255
20241,020
2025836
2026680

Recalls

1 FDA enforcement reports for this application.

  • Aug 31, 2026 · Class II · Ongoing

    Temperature Abuse: Product sat in a non-temperature-controlled FedEx trailer at ambient outdoor conditions for 25.5 hours.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zoladex (Goserelin Acetate)

2024 spending

$716K

Beneficiaries

105

466 claims

Per beneficiary

$6,823

$1,527.27 per unit

View as table
YearSpending
2020$852,389
2021$879,982
2022$849,015
2023$711,421
2024$716,394

Part B: Zoladex (Goserelin Acetate) · HCPCS J9202

2024 spending

$10.3M

Beneficiaries

2,048

8,842 claims

Per beneficiary

$5,032

2024 ASP limit $635.66 per unit

View as table
YearSpending
2020$10,161,257
2021$10,407,420
2022$10,966,920
2023$10,507,401
2024$10,305,181

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 518 on PubMed

Sponsor: Tersera

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.